GigaMune

What GigaMune does

GigaMune Inc. is a privately held, pre-revenue biotechnology company headquartered at 953 Indiana St., San Francisco, developing a pipeline of in vivo cell therapies for hematological malignancies (multiple myeloma and acute myeloblastic leukemia) and inherited disorders including sickle cell disease and Duchenne Muscular Dystrophy (DMD). The company's core proposition is to bypass the ex vivo manufacturing bottleneck inherent to conventional CAR-T therapy by infusing viral gene delivery vectors directly into patients, eliminating the need for lymphodepletion conditioning and its associated medical risks, including infertility.

The technical platform combines three components: (1) an In Vivo Cell Therapy Platform targeting cancer and inherited blood disorders; (2) a Viral Vector Discovery Technology using proprietary algorithms — authored by Robert Edgar (developer of MUSCLE and USEARCH) and published in Nature — to search quadrillions of nucleotides for novel viral receptors and to engineer virus-like particles (VLPs); and (3) high-throughput genomics coupled with AI-driven protein design to identify chimeric antigen receptors and cell-tropic antibodies. The company has assembled a small founding team (1–10 employees) led by Dr. David Johnson, a serial biotech entrepreneur with prior exits at Natera and GigaGen, alongside Dr. Matt Spindler (VP Research), Dr. Everett Meyer (Clinical Adviser), Robert Edgar (Algorithms), and Dr. Eamon Byrne (Senior Scientist). Underlying IP was spun out from GigaGen, though neither GigaGen nor its corporate parent Grifols holds equity in GigaMune.

Commercially, GigaMune is at the earliest stage of company-building: it operates without product revenue, financed by SBIR grants and a pre-seed round (terms undisclosed) from a syndicate of biotech-focused angel and early-stage investors, with planned future commercialization through partnerships with larger pharmaceutical companies. Scientific output is evidenced by eight SBIR grants (cumulative) including awards from NIAMS for DMD gene therapy and NIAID for sickle cell disease, plus podium presentations at PEGS, the CAR/TCR Summit, and the In Vivo Cell Engineering Conference.

Name

GigaMune

Legal name

GigaMune Inc.

Website

https://gigamune.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

GigaMune is a pre-revenue San Francisco biotech developing in vivo cell therapies that use viral vectors and virus-like particles to deliver genes directly to patients, targeting hematological cancers and inherited disorders such as sickle cell disease and Duchenne Muscular Dystrophy.

Ownership category

akta.pro rank

Product category

Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), AAV Vector Gene Therapy Developers (HLAAACAA), CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• In vivo cell therapy
• Viral gene delivery
• Gene therapy pipeline
• CAR-T alternatives
• Virus-like particles

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pre-revenue R&D Stage: GigaMune is a pre-revenue biotechnology company in early development stage. The company is developing a pipeline of in vivo cell therapies and has not yet commercialized any products. Current funding comes from SBIR grants and pre-seed financing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

GigaMune is developing a pipeline of in vivo cell therapies for cancer (multiple myeloma, acute myeloblastic leukemia) and inherited blood disorders (sickle cell disease, Duchenne Muscular Dystrophy). The company's core approach infuses viral gene delivery vectors, including engineered virus-like particles, directly into patients to bypass the ex vivo manufacturing bottleneck of conventional CAR-T cell therapy, removing the need for lymphodepletion conditioning.

Product overview

GigaMune is a single-platform biotechnology company developing a unified in vivo cell therapy technology that solves CAR-T manufacturing bottlenecks by infusing viral gene delivery vectors directly into patients. The platform combines three integrated components: (1) an In Vivo Cell Therapy Platform for treating cancer and blood disorders, (2) a Viral Vector Discovery Technology using algorithms and AI to design targeting capabilities, and (3) Virus Like Particle (VLP) Gene Delivery for precise in vivo transgene delivery. The company is advancing pipeline programs for multiple myeloma, acute myeloblastic leukemia (AML), sickle cell disease, and Duchenne Muscular Dystrophy (DMD).

Differentiator

Problem solved

Functional benefit

Products and services

• In Vivo Cell Therapy Platform An in vivo cell therapy platform that uses viral gene delivery vectors infused directly into patients to treat cancer and inherited blood disorders, eliminating the need for ex vivo cell manufacturing and lymphodepletion conditioning.
• Viral Vector Discovery Technology A discovery technology combining proprietary nucleotide search algorithms, high-throughput genomics, and AI-driven protein design to identify viral envelopes, cell-tropic antibody fragments, and chimeric antigen receptors for precise gene delivery.
• Virus Like Particle (VLP) Gene Delivery Engineered virus-like particles for delivering genes to immune cells and hematopoietic stem cells in vivo, enabling curative transgene delivery without requiring lymphodepletion.

Quantifiable outcome

• Eliminates manufacturing bottleneck of traditional CAR-T cell therapy
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

One partnership is on record.

• GigaGenminorStrategic or Co-development PartnerGigaGen is the source of certain intellectual property that was spun out for GigaMune's technology. Neither GigaGen nor its corporate parent Grifols has any equity stake in GigaMune. Dr. David Johnson is also founder of GigaGen.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company with approved Casgevy therapy for sickle cell disease and beta thalassemia. It targets overlapping inherited blood disorder indications that GigaMune's pipeline also addresses, though with ex vivo editing.
• Allogene Therapeutics: Allogene is a clinical-stage leader in allogeneic (off-the-shelf) CAR-T therapies targeting hematological cancers. While its ex vivo manufacturing approach differs from GigaMune's in vivo method, it competes for the same patient populations and partnership attention from large pharma.
• Beam Therapeutics: Beam Therapeutics is a clinical-stage base editing company with programs in sickle cell disease and other inherited blood disorders. Its overlap with GigaMune's sickle cell program and similar platform-technology orientation makes it a relevant peer.
• Caribou Biosciences: Caribou is a clinical-stage allogeneic CAR-T and iPSC-derived NK cell therapy developer. It shares GigaMune's CAR-T therapeutic space and uses similar high-throughput genomics approaches for receptor discovery, though via ex vivo cell engineering.
• Editas Medicine: Editas Medicine is a clinical-stage gene editing company developing CRISPR-based therapies for inherited blood disorders and oncology. It shares GigaMune's interest in sickle cell disease and in vivo/ex vivo gene correction approaches.

Direct peers

• Capstan Therapeutics: Capstan is a direct peer developing in vivo cell therapies using lipid nanoparticles (LNPs) to deliver mRNA payloads that reprogram immune cells in vivo. It was highlighted alongside GigaMune at the 2023 In Vivo Cell Engineering conference and pursues overlapping hematological cancer and autoimmune indications.
• Interius Biotherapeutics: Interius is developing in vivo CAR-T therapies using viral vectors to genetically modify T cells inside the patient, directly competing with GigaMune's in vivo delivery approach. It was also highlighted at the 2023 In Vivo Cell Engineering conference and targets hematological malignancies.
• Sana Biotechnology: Sana is developing in vivo cell engineering platforms, including fusogen-based delivery to immune cells and stem cells. It was co-featured with GigaMune at the 2023 In Vivo Cell Engineering conference and pursues similar oncology and inherited disease programs with substantially more capital.

Emerging players

• Verve Therapeutics: Verve is a clinical-stage company developing in vivo base editing therapies for cardiovascular disease using lipid nanoparticles. While it targets different indications, it shares GigaMune's in vivo gene-modification paradigm and similar technical risks around delivery to specific cell types.
• Prime Medicine: Prime Medicine is developing prime editing, a next-generation gene editing modality applicable across multiple inherited disorders. It shares GigaMune's interest in inherited disease indications and platform-based approach to multiple programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/gigamuneinc
• LinkedInlinkedin.com/company/gigamune

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GigaMune